NON MALIGNANT DISORDERS
Clinical trials for NON MALIGNANT DISORDERS explained in plain language.
Never miss a new study
Get alerted when new NON MALIGNANT DISORDERS trials appear
Sign up with your email to follow new studies for NON MALIGNANT DISORDERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bone marrow transplant trial offers hope for kids with severe blood disorders
Disease control Recruiting nowThis study tests a bone marrow transplant from a family donor for children under 21 with severe non-cancer blood disorders like sickle cell disease, bone marrow failure, or immune problems. The goal is to see if the transplant can replace the diseased cells with healthy donor cel…
Matched conditions: NON MALIGNANT DISORDERS
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Gentler transplant offers hope for blood disorders without cancer
Disease control Recruiting nowThis study is testing a milder type of stem cell transplant for people with non-cancerous blood, immune, or metabolic disorders. The goal is to safely get donor cells to grow in the patient's body while reducing harsh side effects. About 220 participants will receive a reduced-in…
Matched conditions: NON MALIGNANT DISORDERS
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Personalized dosing may reduce transplant side effects in kids
Knowledge-focused Recruiting nowThis study looks at how the chemotherapy drug treosulfan is processed in children getting a stem cell transplant. The goal is to find the right dose for each child to reduce side effects and improve outcomes. Researchers will measure drug levels in the blood and track how patient…
Matched conditions: NON MALIGNANT DISORDERS
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC